Reveleer vs Amgen

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amgen leads in AI visibility (88 vs 52)
Reveleer logo

Reveleer

ChallengerHealthcare Revenue Cycle & Health IT

Risk Adjustment & Quality Management

AI-powered risk adjustment, quality management, and HEDIS analytics for health plans and ACOs; raised $60M+. Glendale CA;

AI VisibilityBeta
Overall Score
C52
Category Rank
#324 of 596
AI Consensus
69%
Trend
stable
Per Platform
ChatGPT
47
Perplexity
46
Gemini
55

About

Reveleer is a health IT company that provides AI-powered solutions for risk adjustment, quality management, and care gap closure to health plans, ACOs, and provider organizations. Founded in 2014 and headquartered in Glendale, California, Reveleer has raised more than $60 million in growth capital. Its platform combines intelligent document ingestion, natural language processing, and workflow automation to help payers accurately capture risk and close quality gaps at scale, supporting programs like Medicare Advantage, Medicaid Managed Care, and ACA Marketplace.\n\nThe company's core capabilities include automated medical record retrieval, AI-assisted HCC coding review, HEDIS measure tracking, and clinical analytics that surface actionable insights across member populations. Reveleer's platform is designed to serve the full risk adjustment lifecycle from retrospective chart review through prospective care coordination, enabling health plans to improve risk accuracy while simultaneously identifying members who need targeted outreach for quality improvement.\n\nReveleer competes in a market increasingly defined by the financial importance of accurate risk scoring in value-based care contracts. The company has expanded its technology to include an integrated analytics layer that connects risk adjustment and quality data, helping health plans understand the intersection between clinical gaps and revenue impact. Its cloud-native architecture and configurable workflow engine make it adaptable to the specific program requirements of national and regional health plans.

Full profile
Amgen logo

Amgen

LeaderHealthcare Tech

AI Drug Discovery

Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.

AI VisibilityBeta
Overall Score
A88
Category Rank
#3 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
87
Gemini
85

About

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.

Full profile

AI Visibility Head-to-Head

52
Overall Score
88
#324
Category Rank
#3
69
AI Consensus
78
stable
Trend
stable
47
ChatGPT
83
46
Perplexity
87
55
Gemini
85
51
Claude
90
58
Grok
92

Key Details

Category
Risk Adjustment & Quality Management
AI Drug Discovery
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Reveleer
Risk Adjustment & Quality Management
Only Amgen
AI Drug Discovery

Integrations

Amgen is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.